RBC Capital Upgrades AVEO Pharmaceuticals To Sector Perform

Analysts at RBC Capital upgraded

from Underperform to Sector Perform. The price target for AVEO Pharmaceuticals has been raised from $2.00 to $3.00. AVEO Pharmaceuticals shares have dropped 22.28% over the past 52 weeks, while the S&P 500 index has surged 10.34% in the same period. AVEO Pharmaceuticals' shares climbed 14.67% to $1.72 in pre-market trading.